ZhiFeiShengWu Listed in the "2020 China's Top 500 Manufacturing Private Enterprises"

Release time:2020-09-11  |  Click rate:


On September 10, the 2020 China Top 500 Private Enterprises Summit hosted by the All-China Federation of Industry and Commerce was held in Beijing. The list of “Top 500 Chinese Private Enterprises, Top 500 Manufacturing Industries, and Top 100 Service Industries in 2020” was announced at the conference. With this year's excellent market performance and growing enterprise strength, the company is listed in the “2020 China's Top 500 Manufacturing Private Enterprises” for the first time.


(Image source: China Business Times)

This year, in the face of the severe challenges brought by COVID-19, the company seized the opportunity in the crisis to achieve positive growth in its performance. In the first half of this year, the company realized revenue of RMB 6.99 billion with an increase of 38.8%, and a full amount of tax of RMB 812 million with an increase of 19.9%. At the same time, the company insists on putting innovation in the first place, and constantly improves the independent R&D capability. At present, the company has built two R & D bases, set up one R&D center, and set up an expert R&D team with more than 600 people. The company has carried out close cooperation with Institute of Microbiology, Chinese Academy of Sciences, Pasteur Institute, Merck and other companies in the field of vaccines. Since the beginning of this year, the recombinant fusion protein of Mycobacterium tuberculosis independently developed by the company has been officially put on the market, filling the gap of tuberculosis diagnosis in China. The recombinant subunit of COVID-19 vaccine under development has entered phase II clinical trials, with similar technical routes ranking the first in China and leading the world.

This is not only an honor for Zhifei, but also a high recognition from the national authority to be listed in the “2020 China Top 500 Manufacturing Private Enterprises”. In the future, Zhifei will continue to promote the construction of an international R&D and production platform for new vaccines for bacteria, viruses and tuberculosis, lay out several biomedical R&D centers at home and abroad, build a world-class brand integrating prevention and treatment and a national biomedical leading enterprise, and strive for the health cause of our country.